[Analysis of the 2015 British guidelines on the prevention and management of tumor lysis syndrome]

Rev Med Interne. 2017 Jan;38(1):36-43. doi: 10.1016/j.revmed.2016.08.021. Epub 2016 Sep 19.
[Article in French]

Abstract

Whether it appears spontaneously or is induced by therapy, the tumor lysis syndrome is responsible for a massive release of ions and puric bases degradation of products in the circulation exceeding the renal excretion capacity. Some, such as uric acid, xanthine, and calcium phosphate, can precipitate in the renal tubules or parenchyma. It must be known to any practitioner supporting patients with hematologic malignancies, mainly high-grade but also some solid tumors. The 2015 publication of the British recommendations pertaining to patients suffering from hematological diseases should be broadcast. The main goal of treatment is to prevent the occurrence of renal dysfunction associated with heavy morbidity and mortality, either for his own conduct or consequences on obtaining a good tumor response. Some items proposed for the care, whether curative or preventive, should be discussed or detailed, which is the subject of this paper.

Keywords: Acute kidney injury; Guidelines; Insuffisance rénale aiguë; Intensive care; Rasburicase; Recommandations; Réanimation; Syndrome de lyse tumorale; Tumor lysis syndrome.

MeSH terms

  • Adult
  • Allopurinol / therapeutic use
  • Child
  • Hematologic Neoplasms / complications
  • Hematologic Neoplasms / epidemiology
  • Humans
  • Incidence
  • Neoplasms / complications
  • Neoplasms / epidemiology
  • Neoplasms / therapy
  • Practice Guidelines as Topic*
  • Risk Factors
  • Tumor Lysis Syndrome / epidemiology
  • Tumor Lysis Syndrome / etiology
  • Tumor Lysis Syndrome / prevention & control*
  • Tumor Lysis Syndrome / therapy*
  • United Kingdom
  • Uric Acid / urine

Substances

  • Uric Acid
  • Allopurinol